Phatfaves

FDA Calendar: 2H09 Binary Event Trades

Thanks,
Discovery Laboratories, Inc. (DSCO) will be hosting a conference call on Wednesday, July 29, 2009 at 10:00 AM EDT. Management will provide an update on business activities as well as financial results for the second quarter of 2009

FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences

The Current Ratio is 2.20. Current ratios above 1 mean that a company’s shortterm debts are less than its assets. The higher the ratio, the stronger the company’s finances.

Prepare for a Supply Tsunami in Treasurys Next Week

So that is about Z$106,105,600,000,000.0 (zimbabwean)? What comes after a trillion dollars?

The United Nations Intergovernmental Panel on Climate Change (IPCC)

Let (S, f) be a game with n players, where Si is the strategy set for player i, S=S1 X S2 ... X Sn is the set of strategy profiles and f=(f1(x), ..., fn(x)) is the payoff function. Let x − i be a strategy profile of all players except for player i. When each player i \in {1, ..., n} chooses strategy xi resulting in strategy profile x = (x1, ..., xn) then player i obtains payoff fi(x). Note that the payoff depends on the strategy profile chosen, i.e. on the strategy chosen by player i as well as the strategies chosen by all the other players. A strategy profile x* \in S is a Nash equilibrium(NE) if no unilateral deviation in strategy by any single player is profitable for that player, that is

upload.wikimedia.org/m...

A game can have a pure strategy NE or an NE in its mixed extension (that of choosing a pure strategy stochastically with a fixed frequency). Nash proved that if we allow mixed strategies, then every n-player game in which every player can choose from finitely many strategies admits at least one Nash equilibrium.

When the inequality above holds strictly (with > instead of \geq) for all players and all feasible alternative strategies, then the equilibrium is classified as a strict Nash equilibrium. If instead, for some player, there is exact equality between x^*_i and some other strategy in the set S, then the equilibrium is classified as a weak Nash equilibrium.


On Jul 12 09:50 AM Bobiscold wrote:

> The questions are scientific, but the UN answers are political. The
> global warming debate is hardly about science. It has become a cause
> célèbre, championed by activists, politicians and celebrities. To
> deny their belief that humans are the cause of global warming is
> to invoke their wrath. Science is not consensus; Science is theory,
> observation and measurement. Science is not, “let's all take a vote
> on the speed of light and see what number we get.” Science is dictated
> by nature's rules.
> The U.N. would milk the last cow in the paddock, and leave the cow’s
> own calf starving!

Discovery Labs: Panic at the DSCO

FDA Crushed Discovery to a Possible Buy
seekingalpha.com/insta...

Discovery Laboratories is a BUY here, not a sell!

FDA Crushed Discovery to a Possible
seekingalpha.com/insta...


On Jul 05 09:59 PM Phatfaves wrote:

> Will it be GlaxoSmithKline (seekingalpha.com/symbo...) who
> has expressed in writing that the drug Exosurf Neonatal (colfosceril
> palmitate cetyl alcohol, and tyloxapol) Powder for Suspension will
> no longer be marketed and requested that the approval of the applications
> be withdrawn. Effective: June 18, 2009.(www.fda.gov/OHRMS/DOCK...)
>
>
> Or will it be the juggernaut Abbott Laboratories (seekingalpha.com/symbo...)
> Survanta® (beractant) who appears to have dominated the Respiratory
> Distress Syndrome (seekingalpha.com/symbo...) top spot for
> years.
>
> Wednesday, Discovery Laboratories (seekingalpha.com/symbo...)
> stated that Surfaxin will likely face a difficult obstacle with the
> FDA after the agency said it would use a new standard to review the
> drug application.
>
> Wedbush Morgan analyst Kimberly Lee downgraded shares to "Sell" and
> said that Surfaxin is "dead."
>
> How can promising drug be "dead" PEDIATRICS Vol. 115 No. 4 April
> 2005, pp. 1018-1029 (doi:10.1542/10.1542/p... Published A Multicenter,
> Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril
> Palmitate, and Beractant for the Prevention of Respiratory Distress
> Syndrome Among Very Preterm Infants. The study compared the efficacy
> and safety of a novel synthetic surfactant containing a functional
> SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA)
> with those of a non–protein-containing synthetic surfactant (colfosceril
> palmitate; GlaxoSmithKline, Brentford, United Kingdom) and a bovine-derived
> surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the
> prevention of neonatal respiratory distress syndrome (seekingalpha.com/symbo...)
> and RDS-related death.
>
> There conclusion was. " Lucinactant is a more effective surfactant
> preparation than colfosceril palmitate for the prevention of RDS.
> In addition, lucinactant reduces the incidence of BPD, compared with
> colfosceril palmitate, and decreases RDS-related mortality rates,
> compared with beractant. Therefore, we conclude that lucinactant,
> the first of a new class of surfactants containing a functional protein
> analog of SP-B, is an effective therapeutic option for preterm infants
> at risk for RDS."
>
> So at this point who will be sliding its way into owning a promising
> drug at a steal of a price?

FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences

FDA Crushed Discovery to a Possible Buy
seekingalpha.com/user/...

Discovery Laboratories is a BUY here, not a sell!

Will it be GlaxoSmithKline (GSK) who has expressed in writing that the drug Exosurf Neonatal (colfosceril palmitate cetyl alcohol, and tyloxapol) Powder for Suspension will no longer be marketed and requested that the approval of the applications be withdrawn. Effective: June 18, 2009.(www.fda.gov/OHRMS/DOCK...)

Or will it be the juggernaut Abbott Laboratories (ABT) Survanta® (beractant) who appears to have dominated the Respiratory Distress Syndrome (RDS) top spot for years.

Wednesday, Discovery Laboratories (DSCO) stated that Surfaxin will likely face a difficult obstacle with the FDA after the agency said it would use a new standard to review the drug application.

Wedbush Morgan analyst Kimberly Lee downgraded shares to "Sell" and said that Surfaxin is "dead."

How can promising drug be "dead" PEDIATRICS Vol. 115 No. 4 April 2005, pp. 1018-1029 (doi:10.1542/10.1542/p... Published A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants. The study compared the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA) with those of a non–protein-containing synthetic surfactant (colfosceril palmitate; GlaxoSmithKline, Brentford, United Kingdom) and a bovine-derived surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the prevention of neonatal respiratory distress syndrome (RDS) and RDS-related death.

There conclusion was. " Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. In addition, lucinactant reduces the incidence of BPD, compared with colfosceril palmitate, and decreases RDS-related mortality rates, compared with beractant. Therefore, we conclude that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS."

So at this point who will be sliding its way into owning a promising drug at a steal of a price?